Skip to main content
Clinical Trials/NL-OMON26995
NL-OMON26995
Not yet recruiting
Not Applicable

A feasibility study for the use of 18F-Canagliflozin to quantify individual differences in target-site exposure in diabetes patients

niversity Medical Center Groningen0 sites9 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 diabetes mellitus
Sponsor
niversity Medical Center Groningen
Enrollment
9
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Type 2 diabetes
  • Age \= 40 years \<75 years
  • Written informed consent

Exclusion Criteria

  • Pregnant women and women of child\-bearing potential who are not using reliable contraception
  • eGFR \< 30 mL/min/1\.73 m2
  • Subjects on diuretics are allowed to participate but the dose should be stable for at least 4 weeks prior to screening
  • Subjects already on a SGLT2 inhibitor are allowed to participate, but the drug should be interrupted 1 week prior to the first study day till the end of the second study day
  • Subjects using a sulphonylurea.
  • Established peripheral arterial disease
  • Cardiovascular disease: myocardial infarction, angina pectoris, percutanous transluminal coronary angioplasty, coronary artery bypass grafting, stroke, heart failure (NYHA I\-IV) \< 3 months before inclusion
  • History of hypersensitivity to canagliflozin or another SGLT2 inhibitor
  • Active malignancy
  • Donation or loss of 400 ml or more of blood within 8 weeks prior to initial dosing

Outcomes

Primary Outcomes

Not specified

Similar Trials